新型人源化NF1功能缺失型幼年型粒单核细胞白血病小鼠模型
本研究利用CRISPR/Cas9在人脐带血造血干祖细胞中敲除NF1基因,构建人源化NF1功能缺失(NF1LOF)小鼠模型。移植后小鼠快速致死(中位生存32天),出现髓系扩增、组织浸润及RAS/MAPK通路和STAT5基因上调,重现JMML关键特征。
要点
- CRISPR/Cas9敲除NF1基因效率约89%,细胞呈现GM-CSF超敏反应。
- 移植NSG-SGM3小鼠后中位生存32天,伴髓系扩增及脾、肝、肺浸润。
- 该人源化NF1LOF模型重现JMML特征,可用于机制与靶向治疗研究。
核心结论
- 首个NF1LOF人源化小鼠模型重现JMML关键特征,支持疾病机制与靶向治疗研究。
研究设计与样本
- 利用CRISPR/Cas9在人脐带血来源造血干祖细胞(HSPC)中敲除NF1基因,移植入NSG-SGM3小鼠。
主要发现
- NF1基因敲除效率约89%,修饰后HSPC中NF1蛋白同步缺失。
- NF1LOF细胞在体外集落形成单位实验中显示明显GM-CSF超敏反应,模拟JMML。
- 移植NSG-SGM3小鼠后中位生存32天,出现髓系扩增、脾/肝/肺组织浸润及RAS/MAPK通路和STAT5基因特异性上调,与患者特征一致。
关键数值与推荐
- JMML患者中约20%存在NF1功能缺失突变。
- 造血干细胞移植是唯一根治手段,但约50%患者复发。
临床怎么用
- 该模型可用于研究JMML疾病机制和靶向治疗,原文未据此给出临床推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Juvenile myelomonocytic leukemia (JMML) is a fatal pediatric cancer characterized by classical features such as splenomegaly, monocytosis, and granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity, with RAS pathway mutations being the major drivers. Mutations causing loss-of-function of the Neurofibromin 1 gene (NF1LOF) occur in ∼20% of patients with JMML. NF1LOF drives upregulation of RAS/MAPK/PI3K pathways that leads to aggressive proliferation/differentiation of immature myeloid cells. Hematopoietic stem cell transplantation is the only curative option, but relapse occurs in ∼50% of patients, indicating an urgent need for novel and targeted therapeutic strategies. However, low patient sample availability and a lack of reliable disease models have made it difficult to study and treat JMML. Using CRISPR/Cas9, we have generated NF1LOF in human umbilical cord blood-derived hematopoietic stem and progenitor cells (HSPCs). We achieved a high gene knockout rate of ∼89% and concomitant loss of NF1 protein in the modified HSPCs. Importantly, NF1LOF cells displayed marked GM-CSF hypersensitivity in in vitro colony-forming unit assays, mirroring JMML. When transplanted into NSG-SGM3 mice, they caused rapid lethality (median survival of 32 days), myeloid expansion, tissue infiltration (spleen, liver, and lungs), and specific upregulation of RAS/MAPK pathway and STAT5 genes, consistent with patient profiles. This first humanized NF1LOF mouse model recapitulates key JMML features, enabling investigation of disease mechanisms and targeted therapies.
引用
- Sinha R, Patil RV, Romano R, et al. Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia. Blood Adv. 2026. PMID: 41201956. doi:10.1182/bloodadvances.2024015191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。